Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index
Search
EN

Drugs reference index «verteporfin»

verteporfin

Generic Name: verteporfin (VER te PORE fin)Brand Names: Visudyne

What is verteporfin?

Verteporfin works by enhancing the eye's sensitivity to light. Verteporfin affects abnormal blood vessels in the eye.

Verteporfin is used together with "photodynamic" laser light therapy to treat blood vessel disorders in the eye caused by macular degeneration and other eye diseases.

Verteporfin may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about verteporfin?

You should not receive this medication if you are allergic to verteporfin, or if you have porphyria (a genetic enzyme disorder that causes symptoms affecting the skin or nervous system).

Before receiving verteporfin, tell your doctor if you have liver or gallbladder disease, or if you are receiving radiation treatment.

Tell your caregivers if you feel any burning, pain, or swelling around the IV needle when the medicine is injected.

Verteporfin will make your eyes and your skin more sensitive to light. After receiving verteporfin, you must protect your eyes and skin from natural sunlight and bright indoor light for at least 5 days..

Wear dark sunglasses and keep all parts of your skin covered with clothing. Sunscreen will not be effective in protecting you from UV rays during the 5-day period after you have received verteporfin.

What should I discuss with my health care provider before I receive verteporfin?

You should not receive this medication if you are allergic to verteporfin, or if you have porphyria (a genetic enzyme disorder that causes symptoms affecting the skin or nervous system).

If you have certain conditions, you may need a dose adjustment or special tests to safely receive this medication. Before receiving verteporfin, tell your doctor if you have:

  • liver disease;

  • gallbladder disease; or

  • if you are receiving radiation treatment.

FDA pregnancy category C. Verteporfin may be harmful to an unborn baby. Before you receive verteporfin, tell your doctor if you are pregnant. Verteporfin can pass into breast milk and may harm a nursing baby. Do not receive this medication without telling your doctor if you are breast-feeding a baby.

How is verteporfin given?

Verteporfin is given as an injection through a needle placed into a vein. You will receive this injection in a clinic or hospital setting. The medicine must be given slowly through an IV infusion, and can take at least 10 minutes to complete.

Tell your caregivers if you feel any burning, pain, or swelling around the IV needle when the medicine is injected.

You will receive laser light treatment to your eye(s) within 15 minutes after the start of your verteporfin infusion.

After receiving verteporfin, you must protect your eyes from natural sunlight and bright indoor light for at least 5 days.. For best protection, wear dark sunglasses whenever you are outdoors or while indoors under bright lighting.

You should not stay in the dark while you are indoors, as this can actually cause the drug to stay active in your body longer. It is best to spend your time in ambient indoor light such as indirect sunlight through a window, or low-wattage incandescent lighting. Avoid areas where you will be exposed to halogen or fluorescent light.

What happens if I miss a dose?

Since verteporfin is given by a healthcare professional only in preparation for laser light treatment, you will not be on a dosing schedule.

What happens if I overdose?

Seek emergency medical attention if you think you have received too much of this medicine.

Overdose symptoms may include severely decreased vision.

What should I avoid after I receive verteporfin?

Verteporfin will make your eyes and your skin more sensitive to light. Natural sunlight and bright indoor light can expose you to harmful UV rays, which may cause severe sunburn or damage to your vision.

Avoid exposure to sunlight, tanning beds, bright halogen lights, or other bright lighting for at least 5 days after you are treated with verteporfin.

To avoid exposing your skin to sunlight, keep all parts of your skin covered with clothing. Sunscreen will not be effective in protecting you from UV rays during the 5-day period after you have received verteporfin.

Verteporfin can cause side effects that may impair your vision. Be careful if you drive or do anything that requires you to be able to see clearly.

Verteporfin side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; sweating; dizziness; swelling of your face, lips, tongue, or throat. Tell your caregivers at once if you have a serious side effect such as:
  • severe decrease in vision;

  • sudden and severe pain;

  • severe redness or other discoloration of your eyes;

  • eye pain or seeing halos around lights;

  • feeling like you might pass out;

  • chest pain; or

  • warmth or tingly feeling under your skin.

Less serious side effects may include:

  • slight changes in your vision, seeing flashes of light;

  • dry eyes;

  • redness, swelling, or itching of your eyelids;

  • seeing flashes of light;

  • headache;

  • weak or tired feeling;

  • mild itching or skin rash;

  • constipation, nausea;

  • joint pain, muscle weakness;

  • fever, chills, body aches, sore throat, flu symptoms; or

  • pain, swelling, bleeding, or itching where the medicine was injected.

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

Verteporfin Dosing Information

Usual Adult Dose for Macular Degeneration:

Subfoveal choroidal neovascularization: 6 mg/m2 body surface area intravenously over 10 minutes, once. The drug is photoactivated by 83 seconds of laser light administration (689 nm) commencing 15 minutes after start of the infusion.Bilateral lesions in patients who have never undergone verteporfin therapy: 6 mg/m2 body surface area intravenously over 10 minutes, once. The drug is photoactivated by 83 seconds of laser light administration (689 nm) commencing 15 minutes after start of the infusion. The most aggressive lesion should be treated first. If, after the first treatment, an acceptable safety profile is identified, treatment of the second eye can commence no sooner than one week following the first course. Bilateral lesions in patients who have undergone previous verteporfin therapy: 6 mg/m2 body surface area intravenously over 10 minutes, once. The drug is photoactivated by 83 seconds of laser light administration (689 nm) commencing 15 minutes after start of the infusion. If the patient showed an acceptable safety profile following the first course of verteporfin therapy then both eyes may be treated concurrently after a single administration of verteporfin. The more aggressive lesion should be treated first 15 minutes after the start of the verteporfin infusion. The treatment of the second eye should be initiated immediately at the end of the light treatment of the first eye using the same light dose and intensity as for the first eye. The treatment of the second eye should start no later than 20 minutes after the start of the verteporfin infusion.Patients may be retreated in 3 months, if necessary.

Usual Geriatric Dose for Macular Degeneration:

Subfoveal choroidal neovascularization: 6 mg/m2 body surface area intravenously over 10 minutes, once. The drug is photoactivated by 83 seconds of laser light administration (689 nm) commencing 15 minutes after start of the infusion.Bilateral lesions in patients who have never undergone verteporfin therapy: 6 mg/m2 body surface area intravenously over 10 minutes, once. The drug is photoactivated by 83 seconds of laser light administration (689 nm) commencing 15 minutes after start of the infusion. The most aggressive lesion should be treated first. If, after the first treatment, an acceptable safety profile is identified, treatment of the second eye can commence no sooner than one week following the first course. Bilateral lesions in patients who have undergone previous verteporfin therapy: 6 mg/m2 body surface area intravenously over 10 minutes, once. The drug is photoactivated by 83 seconds of laser light administration (689 nm) commencing 15 minutes after start of the infusion. If the patient showed an acceptable safety profile following the first course of verteporfin therapy then both eyes may be treated concurrently after a single administration of verteporfin. The more aggressive lesion should be treated first 15 minutes after the start of the verteporfin infusion. The treatment of the second eye should be initiated immediately at the end of the light treatment of the first eye using the same light dose and intensity as for the first eye. The treatment of the second eye should start no later than 20 minutes after the start of the verteporfin infusion.A decreased treatment effect has been reported in elderly patientsPatients may be retreated in 3 months, if necessary.

What other drugs will affect verteporfin?

The following drugs can interact with verteporfin. Tell your doctor if you are using any of these:

  • dimethyl sulfoxide (Rimso-50);

  • griseofulvin (Fulvicin, Grisactin);

  • polymyxin B (Polytrim, AK-Poly-Bac, Ocumycin, Polysporin Ophthalmic, Polytracin Ophthalmic);

  • diabetes medications you take by mouth;

  • birth control pills;

  • a diuretic (water pill);

  • a sulfa drug (Bactrim, Gantanol, Septra, and others);

  • medication used to prevent blood clots, such as alteplase (Activase), anistreplase (Eminase), clopidogrel (Plavix), dipyridamole (Persantine), streptokinase (Kabikinase, Streptase), ticlopidine (Ticlid), and urokinase (Abbokinase);

  • medicine to treat mental illness, such as chlorpromazine (Thorazine), fluphenazine (Prolixin), mesoridazine (Serentil), perphenazine (Trilafon), prochlorperazine (Compazine), thioridazine (Mellaril), or trifluperazine (Stelazine);

  • an antibiotic such as ciprofloxacin (Cipro), ofloxacin (Floxin), norfloxacin (Noroxin), levofloxacin (Levaquin), lomefloxacin (Maxaquin), and others;

  • a tetracycline antibiotic such as demeclocycline (Declomycin), doxycycline (Adoxa, Doryx, Oracea, Vibramycin), minocycline (Dynacin, Minocin, Solodyn, Vectrin), or tetracycline (Brodspec, Panmycin, Sumycin, Tetracap); or

  • a calcium channel blocker such as amlodipine (Norvasc), diltiazem (Tiazac, Cartia, Cardizem), nifedipine (Procardia, Adalat), verapamil (Calan, Covera, Isoptin, Verelan), and others.

This list is not complete and there may be other drugs that can interact with verteporfin. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

Where can I get more information?

  • Your doctor or pharmacist can provide more information about verteporfin.
  • Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2006 Cerner Multum, Inc. Version: 1.03. Revision Date: 4/12/2009 4:44:16 PM.
  • verteporfin Intravenous, Injection Advanced Consumer (Micromedex) - Includes Dosage Information
  • Verteporfin MedFacts Consumer Leaflet (Wolters Kluwer)
  • Visudyne Prescribing Information (FDA)

Comment «verteporfin»